Search results
Results from the WOW.Com Content Network
The American Academy of Neurology (AAN) is a professional society representing over 40,000 neurologists and neuroscientists. [1] As a medical specialty society it was established in 1948 by A.B. Baker of the University of Minnesota to advance the art and science of neurology, and thereby promote the best possible care for patients with neurological disorders.
At the annual 2020 American Academy of Neurology meeting, Tilton gave an informal "Head Talk" on the neurology of the Salem Witch Trials. [11] She repeated the talk in 2021 [ 12 ] and 2023. [ 13 ] In 2022, she gave a "Head Talk" on whether neurological disorders could change the course of history.
The award recognizes an individual who has made seminal research contributions in the search for the cause, prevention of, and cure for amyotrophic lateral sclerosis . The award includes a trophy, a $50,000 prize, and a 20-minute lecture at the American Academy of Neurology annual meeting. The prize is named after Sheila Essey (wife of Richard ...
The prize is awarded for achievements on emerging areas of research in Pick's disease, Alzheimer's disease and other dementias. [ 1] The award includes a medallion, $100,000 prize, and a 20-minute lecture at the American Academy of Neurology annual meeting. The prize is named after Luba Potamkin (wife of Victor Potamkin) who, in 1978, was ...
About 1.5 to 3.8 million sports-related concussions occur annually in the U.S., according to the American Academy of Neurology. Concussions affect millions of kids and teens a year. Concussions ...
At the national meetings of the American Academy of Neurology, Dr. Samuels created and on several occasions presented "The Borderlands of Neurology and Internal Medicine," the only one-person, full-day course ever presented; he was asked to convene a similar course at the World Congress of Neurology in 2005 in Sydney, Australia. He delivered a ...
Global Principal Investigator of the ACT (Avonex Combination Trial) clinical trialGlobal Principal Investigator of the TRANSFORMS Phase III trial of Fingolimod, a novel oral agent for use in treating Multiple Sclerosis, the primary results of which were presented at the American Academy of Neurology Annual Meeting in May 2009.
Norman Geschwind was born on January 8, 1926, in New York City, New York to a Jewish family. He was a student at Boy's High School in Brooklyn, New York. He matriculated into Harvard University in 1942, initially planning to study mathematics. His education was interrupted when drafted into the Army in 1944.